Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
1 Division of Experimental Oncology E, National Cancer Institute, Naples
2 Department of Surgical Pathology, National Cancer Institute, Naples
3 Division of Medical Oncology B, National Cancer Institute, Naples
4 Division of Gynecology, National Cancer Institute, Naples
5 Division of Gynecology, Casa Sollievo della Sofferenza, S.Giovanni Rotondo
6 Division of Radiotherapy, National Cancer Institute, Naples
7 Clinical Trials Unit, National Cancer Institute, Naples
Abstract
C-erbB2 is over-expressed or amplified in many carcinomas. We assessed the relationship between erb-B2 immunoreactivity, and its predictive role in progression-free survival and treatment outcome in patients with cervical carcinoma. Sections from 65 cervical carcinoma were immunostained with antibody to p185 erbB2. Immunoreactive ErbB2 was found in 25 patients (38%) [+ 15 pts. (23%); ++ 10 pts. (15%)]. There were no correlation with age, performance status, grading and histology. Erb-B2 immunoreactivity significantly correlated with stage of the disease. Positive immunoreactivity was found in 63%, 44%, 14% and 0% of stage I, II, III and IV carcinomas, (p = 0.0045). Progression-free survival was longer in erb-B2 positive patients without reaching significance. No correlation was found between erbB2 and response to radiotherapy or chemotherapy. In conclusion, a significant proportion of stage I and II cervical cancer express erb-B2 compared to more advanced stages. Expression of the oncogene does not appear to be related to prognosis or treatment outcome.
Keywords
- erb-b2
- Cervical Cancer
- Cervix
- Tumor
- Cancer
- Neoplasia
- Squamous Cell Carcinoma
- Adenocarcinoma